MeiraGTx Holdings PLC (FRA:328)
€ 6.35 0.25 (4.1%) Market Cap: 492.19 Mil Enterprise Value: 457.91 Mil PE Ratio: 0 PB Ratio: 5.50 GF Score: 47/100

MeiraGTx Holdings PLC at Barclays Global Healthcare Conference Transcript

Mar 12, 2019 / 06:35PM GMT
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon. My name is Gena Wang. I'm a SMID cap biotech analyst from Barclays. It is my great pleasure to introduce our next speaker, Zandy Forbes, Chief Executive Officer and the President of MeiraGTx.

Alexandria Forbes
MeiraGTx Holdings plc - CEO, President & Director

Thank you, Gena, and thank you to Barclays for inviting me to speak about Meira today. I'll just bring your attention to our forward-looking statement and move on to an overview of the company.

We were formed just under 4 years ago as a private company with the aim of developing gene therapies to treat a multitude of different diseases, not just rare diseases but many different diseases in a cost-effective way. So in setting up the company, we established a number of things that is required for a gene therapy company in general. One of the first things that we took into the company on formation is forward-looking technology to be able to regulate transgenes. This is something that many groups have looked for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot